Sanofi Japan Looks Past Plavix Hit To New Launches
This article was originally published in PharmAsia News
Executive Summary
Sanofi is facing a self-described “transitional period” in Japan and a couple of years of sales contraction as major products are opened up to generics. But the plan is to conduct more than 20 launches, including several biologics and line extensions, in the next four years, its new country president says.